Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With Telaprevir

Data Monitoring Committee appointed for Part B

Masking:

Part A: Open Label Part B: Double Blind

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com.

Inclusion Criteria:

- Chronic hepatitis C genotype 1. GT-1b Capped at 50 % of naïve subjects

- Naives to prior anti-HCV therapy [Interferon (IFN) and direct antiviral agent (DAA)
based]

- Relapsers (defined as subjects who had undetectable HCV ribonucleic acid (RNA) on
prior treatment regimen of alfa-2a/RBV and Hepatitis C Virus (HCV) RNA > 25IU/mL
after discontinuation of treatment). Capped at 20%

- HCV RNA ≥ 100,000 IU/mL

- Subjects with compensated cirrhosis can be enrolled and will be capped at
approximately 10%

- Seronegative for human immunodeficiency virus (HIV) and hepatitis B surface antigen
(HBsAg)

- Men or women, 18-70 years of age

Exclusion Criteria:

- Chronic liver disease due to causes other than chronic HCV

- Current or past evidence of decompensation

- Conditions that preclude the use of Alfa/RBV/TVR per respective labels

- Diagnosed or suspected hepatocellular carcinoma